Skip to search formSkip to main contentSkip to account menu

efaproxiral

Known as: 2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid, 2-Dacmpp, Efaproxyn 
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (4)

Aniline CompoundsAntisickling AgentsPropionatesRadiation-Sensitizing Agents

Narrower (3)

Efaproxiral SodiumRSR 13RSR 56

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
CNS Complications of Breast Cancer
In general, the development of CNS metastases of breast cancer depends on several prognostic factors, including younger age and a… 
2006
2006
Efaproxiral: should we hold our breath?
Suh et al breathe a bit of new life into two long-standing endeavors with their report in this issue of a phase III study of… 
Review
2006
Review
2006
Role of efaproxiral in metastatic brain tumors
Brain metastases from breast cancer are common and cause significant morbidity and mortality. Treatment with whole-brain… 
2006
2006
Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
Review
2006
Review
2006
Cerebral metastases—a therapeutic update
Cerebral metastases remain a common complication among patients with cancer. Historically, whole-brain radiotherapy has remained… 
2005
2005
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
PURPOSE Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We… 
2004
2004
Efaproxiral: a novel radiation sensitiser
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. By facilitating… 
2004
2004
Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy.
3090 Background: Tumor hypoxia is known to decrease radiation sensitivity of solid tumors. RSR13, a novel radiation sensitizer… 
2004
2004
Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009).
1561 Background: 538 patients with brain metastases from selected solid tumors were randomized in a study of standard WBRT (30 Gy… 
Review
2003
Review
2003
Efaproxiral (Allos Therapeutics).
  • A. Kolman
  • IDrugs : the investigational drugs journal
  • 2003
  • Corpus ID: 10639073
Allos Therapeutics Inc is developing the hemoglobin allosteric modifier efaproxiral as a potential radiosensitizer and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)